Symptomatic Carotid Arteries: Early or Late Emergency Revascularization?

Carotid endarterectomy continues to be the safest technique for emergency revascularization. However, 48 hours after index event, different strategy outcomes will become comparable. 

Carótidas sintomáticas: ¿revascularización urgente, precoz o retardada?

Multiple advances in device development have brought promising results for carotid revascularization patients with symptomatic stenosis. Regardless these developments, optimal revascularization timing after index event remains unclear

This study included patients with symptomatic carotid stenosis undergoing transcarotid artery revascularization (TCAR), transfemoral carotid stenting (TFCAS), or carotid endarterectomy (CEA) at different times after index event. 

Procedures were regarded as urgent (0 to 2 days after last event), early (3 to 14 days) or late (15 to 180 days).

Primary end point was inhospital death or stroke. Secondary end point added transient ischemic event. 

The study included 18,643 symptomatic revascularizations: 10.8% were urgent, 39.8% were early, and the remaining half was late.


Read also:  TICO: Age Impacts the Effect of Antiplatelet Monotherapy.


Patients undergoing TFCAS showed the highest rate of stroke and death at all timing cohorts. 

Among urgent cases, CAE had 4% events vs 6.9% for TFCAS and 6.5% for TCAR (p=0.018). These differences tended to level off the later patients were treated. 

When adjusting for risk, OR resulted similar between patients undergoing CAE and TCAR. 

Conclusion

CAE continues to be the safest revascularization approach for emergency cases. TCAR and CAE seem similar after 48 hours. 

Original Title: In-Hospital Outcomes of Urgent, Early, or Late Revascularization for Symptomatic Carotid Artery Stenosis.

Reference: Christina L. Cui et al. J Am Heart Assoc. 2021 Dec 21;10(24):e022700. doi: 10.1161/JAHA.121.022700.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...